A5055389521- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
- Crystallization and Solubility Studies
- X-ray Diffraction in Crystallography
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Screening and Detection
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Acute Lymphoblastic Leukemia research
- Chemical Reaction Mechanisms
- Nutrition and Health in Aging
- Nutritional Studies and Diet
- Hepatocellular Carcinoma Treatment and Prognosis
- Neutropenia and Cancer Infections
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Chronic Lymphocytic Leukemia Research
- Esophageal Cancer Research and Treatment
- Genetic and phenotypic traits in livestock
Dana-Farber Cancer Institute
2015-2024
Centre National de la Recherche Scientifique
2021-2024
Harvard University
2015-2024
CancerCare
2000-2024
Institut de Science et d'Ingénierie Supramoléculaires
2021-2024
Université de Strasbourg
2021-2024
Technical University of Munich
2024
Ludwig-Maximilians-Universität München
2015-2024
Boeing (Australia)
2006-2024
Fondation Jean-Marie Lehn
2023-2024
To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory colorectal cancer whose tumors express epidermal growth factor receptor.Phase II, open-label clinical trial. Patients were required to have EGFr expression demonstrated on formalin-fixed paraffin-embedded tumor tissue by immunohistochemical staining before study participation. received irinotecan, either alone or a combination regimen, failure this regimen entry. Cetuximab was...
About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated cytarabine and an anthracycline. However, such responses are rarely durable conventional postremission therapy is administered. Uncontrolled trials have suggested that intensive may prolong these remissions.We 1088 newly diagnosed AML three days daunorubicin seven randomly assigned patients who had a to receive four courses at one doses: 100 mg per square meter...
The primary treatment modality for patients with carcinoma of the esophagus or gastroesophageal junction has been surgery, although radiation therapy concurrent chemotherapy produces similar results. As both have curative potential, there great interest in use trimodality therapy. To this end, we compared survival, response, and patterns failure to esophagectomy alone nonmetastatic esophageal cancer.Four hundred seventy-five eligible were planned enrollment. Patients randomly assigned either...
Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent combines trifluridine and tipiracil hydrochloride, was effective the treatment of refractory colorectal cancer. We a phase 3 trial to further assess efficacy safety TAS-102 global population such patients.In this double-blind study, we randomly assigned 800 patients, 2:1 ratio, receive or placebo. The primary end point overall survival.The median survival improved from 5.3 months with placebo 7.1 hazard...
The combination of radiation therapy and chemotherapy with fluorouracil plus semustine after surgery has been established as an effective approach to decreasing the risk tumor relapse improving survival in patients rectal cancer who are at high for or death. We sought determine whether efficacy could be improved by administering protracted infusion throughout duration omission would reduce toxicity delayed complications without its antitumor efficacy.
To determine the relationship, in patients with adenocarcinoma of colon, between survival and number lymph nodes analyzed from surgical specimens.Intergroup Trial INT-0089 is a mature trial adjuvant chemotherapy for high-risk stage II III colon cancer. We performed secondary analysis this group overall (OS) as main end point. Cause-specific (CSS) disease-free were points. Rates these outcome measures estimated using Kaplan-Meier methodology. Log-rank test was used to compare curves, Cox...
The combination of gemcitabine plus bevacizumab produced a 21% response rate and median survival 8.8 months in multicenter phase II trial patients with metastatic pancreatic cancer. These encouraging data led Cancer Leukemia Group B (CALGB) to conduct double-blind, placebo-controlled, randomized III gemcitabine/bevacizumab versus gemcitabine/placebo advanced cancer patients.
<h3>Importance</h3> Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients advanced or metastatic colorectal cancer, but the optimal choice of initial therapy in previously untreated is unknown. <h3>Objective</h3> To determine if addition cetuximab vs bevacizumab combination leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen irinotecan (FOLFIRI) superior as first-line metastatic<i>KRAS</i>wild-type (wt) cancer....
Regular physical activity reduces the risk of developing colon cancer, however, its influence on patients with established disease is unknown.We conducted a prospective observational study 832 stage III cancer enrolled in randomized adjuvant chemotherapy trial. Patients reported various recreational activities approximately 6 months after completion therapy and were observed for recurrence or death. To minimize bias by occult recurrence, we excluded who experienced died within 90 days their...
PURPOSE The goal of this study was to determine the efficacy intensive-course fluorouracil (5FU) plus low-dose leucovorin given for 6 months following potentially curative resection colon cancer. PATIENTS AND METHODS Three hundred seventeen patients with high-risk stage II or III cancer were randomly assigned 3 4 weeks surgery receive either (1) chemotherapy six cycles 5FU (425 mg/m2) (20 by rapid intravenous injection daily 5 consecutive days every weeks, (2) observation. RESULTS median...
We postulated that the pathologic evaluation of lymph nodes surgical specimens from patients with rectal cancer can have a substantial impact on time to relapse and survival.We analyzed data 1,664 T3, T4, or node-positive treated in national intergroup trial adjuvant therapy chemotherapy radiation therapy. Associations between number found by pathologist specimen survival outcomes were investigated.Patients divided into groups nodal status corresponding quartiles numbers examined. The...
A total of 343 patients with previously untreated metastatic measurable colorectal carcinoma were studied to evaluate the impact on toxicity, response, and survival leucovorin-modulated fluorouracil (5-FU). maximally tolerated intravenous bolus loading course regimen 5-FU alone (500 mg/m2 x 5 days every 4 weeks 25 escalation) was compared a high-dose leucovorin (600 500 weekly for 6 2-week rest) similar low-dose rest). The dose-limiting toxicity two regimens gastrointestinal, specifically...
Purpose On initial publication of GI Intergroup Radiation Therapy Oncology Group (RTOG) 98-11 [A Phase III Randomized Study 5-Fluorouracil (5-FU), Mitomycin, and Radiotherapy Versus 5-Fluorouracil, Cisplatin in Carcinoma the Anal Canal], concurrent chemoradiation (CCR) with fluorouracil (FU) plus mitomycin (MMC) decreased colostomy failure (CF) when compared induction FU cisplatin (CDDP), but did not significantly impact disease-free survival (DFS) or overall (OS) for anal canal carcinoma....
This multicenter study evaluated the antitumor activity of cetuximab, an immunoglobulin G1 antibody directed at epidermal growth factor receptor (EGFR), in metastatic colorectal carcinoma (CRC) refractory to irinotecan, oxaliplatin, and a fluoropyrimidine. It also safety, pharmacokinetics, immunokinetics, biologic determinants activity.Patients with CRC, whose tumors demonstrated EGFR immunostaining were fluoropyrimidines, treated cetuximab loading dose 400 mg/m2 followed by 250 weekly. An...
Purpose Colorectal cancer is the second leading cause of deaths in United States, with poor survival predicted by regional lymph node (LN) metastasis. The impact LN ratio (LNR) on unknown this disease. Patients and Methods We analyzed data from Intergroup trial 0089 adjuvant chemotherapy for stage II III patients colon cancer, which all received fluorouracil-based therapy. Survival was similar arms study, allowing us to evaluate together. End points included overall (OS), cancer-specific...